Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors

✍ Scribed by Yoffi Segall; Gary B. Quistad; Daniel K. Nomura; John E. Casida

• Book ID: 104364039
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 132 KB
• Volume: 13
• Category: Article
• ISSN: 0960-894X
• DOI: 10.1016/s0960-894x(03)00721-2

✦ Synopsis

Arachidonylsulfonyl fluoride (3), reported here for the first time, is similar in potency to its known methyl arachidonylfluorophosphonate (2) analogue as an inhibitor of mouse brain fatty acid amide hydrolase activity (IC(50) 0.1 nM) and cannabinoid CB1 agonist [3H]CP 55,940 binding (IC(50) 304-530 nM). Interestingly, 3 is much more selective than 2 as an inhibitor for fatty acid amide hydrolase relative to acetylcholinesterase, butyrylcholinesterase and neuropathy target esterase. N-(2-Hydroxyethyl)arachidonylsulfonamide (4) is at least 2500-fold less potent than N-(2-hydroxyethyl)arachidonamide (anandamide) (1) at the CB1 agonist site.